Literature DB >> 15150679

Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men.

E F L Dubois1, M G M Derks, D H Schweitzer, A H Zwinderman, P N R Dekhuijzen, C J van Boxtel.   

Abstract

OBJECTIVE: To compare potency and efficacy of dexamethasone (DEXA) and prednisolone (PRED) in assumed equipotent doses in combination with endogenous cortisol, using lymphocyte counts, plasma osteocalcin (OC), and eosinophilic cationic protein (ECP) as effect variables and to evaluate potential differences between healthy subjects and asthmatic patients.
METHODS: Eight healthy subjects and six asthmatic patients who had stopped taking their regular inhaled glucocorticosteroid treatment (ICS) for 1 week, were given an IV bolus of DEXA and PRED in assumed equipotent doses of 2.0 mg and 12.5 mg, respectively, on separate occasions, in combination with subcutaneously injected granulocyte-colony-stimulating factor (G-CSF) as a stimulant for ECP production. Plasma levels of DEXA, PRED, cortisol and effect variables were determined over 25 h and pharmacokinetic-pharmacodynamic (PK-PD) modelling was performed.
RESULTS: Baseline cortisol concentration was lower in patients than in healthy subjects. Both of the exogenous glucocorticoids (GCs) diminished cortisol production. In the healthy subjects, the cortisol production remained suppressed for the full duration of the study day after DEXA but not after PRED. In the asthmatic patients though, the reappearance of the endogenous production of cortisol was seen after both DEXA and PRED. The E(max) values for lymphocyte counts and OC showed that cortisol acted as partial, and DEXA and PRED as full agonists. The observed responses of DEXA and PRED suppressing cortisol, OC and lymphocyte counts were all of the same relative order of magnitude, in accordance with the estimated PD parameters. However, cortisol was estimated to have very little effect on ECP and modelling further predicted that DEXA and PRED were only partial agonists for this effect, without a difference between healthy and asthmatic subjects. Yet, in healthy subjects, the area under the concentration-time curves (AUCs) indicated unexpectedly that ECP was only suppressed after PRED and not after DEXA, while in patients it was suppressed after both GCs. The rank order of potency on lymphocyte counts, OC and ECP was DEXA>PRED>cortisol, although the different relative potencies of the three GCs involved were not the same for all of the three effect variables and differences were also found between healthy and asthmatic subjects.
CONCLUSION: PK-PD modelling studies of GCs demonstrated not only differences in potency of DEXA and PRED on the measured systemic markers, but also different potencies per target tissue and differences between healthy and asthmatic men. The effects caused by the achieved blood concentrations of DEXA and PRED, expressed as AUCs of the effect variables, were in accordance with their respective E(max) values in case of the lymphocytes and OC but not for ECP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150679     DOI: 10.1007/s00228-004-0738-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids.

Authors:  J D Leuppi; C M Salome; C R Jenkins; S D Anderson; W Xuan; G B Marks; H Koskela; J D Brannan; R Freed; M Andersson; H K Chan; A J Woolcock
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

2.  Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone.

Authors:  J A Wald; W J Jusko
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

3.  The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma.

Authors:  A M Wever; J Wever-Hess; J Hermans
Journal:  Clin Exp Allergy       Date:  1997-05       Impact factor: 5.018

4.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

Review 5.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

6.  Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone.

Authors:  J L Malo; A Cartier; H Ghezzo; S Mark; J Brown; M Laviolette; L P Boulet
Journal:  Eur Respir J       Date:  1999-05       Impact factor: 16.671

7.  The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects.

Authors:  H K Nielsen; P Charles; L Mosekilde
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958

8.  Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps.

Authors:  J Mullol; A Xaubet; E López; J Roca-Ferrer; C Picado
Journal:  Thorax       Date:  1995-03       Impact factor: 9.139

9.  Distinct actions of prednisolone and dexamethasone towards osteocalcin and eosinophilic cationic protein in assumed clinically equivalent doses: a study in healthy men.

Authors:  E F L Dubois; M G M Derks; A H Zwinderman; P N R Dekhuijzen; C J Van Boxtel; D H Schweitzer
Journal:  Eur J Clin Pharmacol       Date:  2003-02-15       Impact factor: 2.953

10.  Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model.

Authors:  R P Koopmans; M C Braat; B Oosterhuis; C J van Boxtel
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

View more
  1 in total

1.  Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women.

Authors:  Wojciech Krzyzanski; Mark A Milad; Alan H Jobe; Thomas Peppard; Robert R Bies; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-05       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.